EPIX 6.08 ESSA Pharma Inc.
| Range: | 3.8-11.67 | Vol Avg: | 56535 | Last Div: | 0 | Changes: | 0.31 |
| Beta: | 1.84 | Cap: | 0.27B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Mar 13 2015 | Empoloyees: | 50 | ||
| CUSIP: | 29668H708 | CIK: | 0001633932 | ISIN: | CA29668H7085 | Country: | CA |
| CEO: | Dr. David Ross Parkinson M.D. | Website: | https://www.essapharma.com | ||||
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Stock Details
EPIX 17
Oppenheimer Reiterates Outperform Rating on ESSA Pharma (EPIX)
Leland Gershell·Mon Sep 16 2024
Oppenheimer
EPIX 15
Piper Sandler Reiterates Overweight Rating on ESSA Pharma (EPIX)
Tyler Van Buren·Mon Sep 16 2024
Piper Sandler
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow